Released Nov 13, 2020, before the open
10-Q filed Nov 13, 2020, 44 days after period end · 0001493152-20-021342
Q3 2020 · 10-Q
Revenue$1.48M$1.48M −67.8% vs Q3 2019+95.9% vs Q2 2020
Net Income-$2.02M-$2.02M N/M vs Q3 2019N/M vs Q2 2020
EPS Diluted-$0.11-$0.11 N/M vs Q3 2019N/M vs Q2 2020
Operating Income-$2,007,586N/M
Operating Cash Flowderived-$2,406,663N/M
Free Cash Flowderived-$2,406,663N/M
Margins · derived
Operating margin-135.9%−129.0 pt vs Q3 2019
Net margin-136.8%−129.1 pt vs Q3 2019
What the release said
The release
Same quarter
| Metric | Q3 2020 | Q3 2019 | Q3 2018 | Q3 2017 |
|---|---|---|---|---|
| Revenue | $1.48M | $4.58M | $6.00M | $5.20M |
| Net Income | -$2.02M | -$351.00K | $222.00K | -$184.00K |
| EPS Diluted | -$0.11 | -$0.12 | $0.08 | -$0.07 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Ernexa Therapeutics Inc. · CIK 748592 · Engraved from SEC EDGAR